- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sanarus introduces breast biopsy
Pleasanton, CA-based Sanarus Medical may soon bring to market an ultrasound-guided biopsy tool called Centrica. The product, described as a rotational core biopsy system, uses a new approach to breast tissue sampling that the company considers more
Pleasanton, CA-based Sanarus Medical may soon bring to market an ultrasound-guided biopsy tool called Centrica. The product, described as a rotational core biopsy system, uses a new approach to breast tissue sampling that the company considers more cost-effective and less invasive than open, surgical biopsy options. The procedure creates a 3 to 4-mm incision in the breast and requires no general anesthesia or stitches. Under ultrasound visualization, a small needle is placed directly into the tissue. Once placement is confirmed via ultrasound, the immobilized lesion is “stick frozen” for a few seconds, which secures the targeted tissue and enables a large tissue sample to be removed for evaluation. Centrica, which has been cleared by the FDA, is the first in a series of ultrasound-guided technologies being developed by Sanarus.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
